{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:44:44Z","timestamp":1777927484169,"version":"3.51.4"},"reference-count":22,"publisher":"SAGE Publications","issue":"14","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:p>\n                    Limited information is available regarding the efficacy of antiretrovirals in people with HIV-1 and high or very high Body Mass Index (BMI). This is especially the case for the alafenamide salt of tenofovir as clinical trials have only enrolled patients with BMI \u226430 kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    . Lower concentrations of some antiretrovirals are expected in patients with BMI &gt;30 kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    due to potential changes in clearance and distribution of medication. This report describes an individual taking tenofovir alafenamide, emtricitabine and efavirenz in whom HIV-1 viral load was consistently undetectable (&lt;50 copies\/ml) over a 2.5 year period. During this period the patient\u2019s BMI ranged between 59.8 and 68.1\u00a0kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    . Further data is required to support the efficacy of antiretrovirals in individuals with high and very high BMI.\n                  <\/jats:p>","DOI":"10.1177\/09564624231195088","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T03:12:40Z","timestamp":1692328360000},"page":"1072-1074","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effective prolonged suppression of HIV-1 viral load using tenofovir alafenamide, emtricitabine and efavirenz in an adult with BMI &gt;59 kg\/m\n                    <sup>2<\/sup>"],"prefix":"10.1177","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0608-9584","authenticated-orcid":false,"given":"Muhammad","family":"Ali","sequence":"first","affiliation":[{"name":"UCL Hospitals NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel","family":"Lee","sequence":"additional","affiliation":[{"name":"UCL Hospitals NHS Trust, London, UK"},{"name":"Bloomsbury Clinic, CNWL NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"French","sequence":"additional","affiliation":[{"name":"UCL Hospitals NHS Trust, London, UK"},{"name":"Bloomsbury Clinic, CNWL NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Miller","sequence":"additional","affiliation":[{"name":"UCL Hospitals NHS Trust, London, UK"},{"name":"Bloomsbury Clinic, CNWL NHS Trust, London, UK"},{"name":"Centre for Sexual Health and HIV Research, Institute for Global Health, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3600-5394","authenticated-orcid":false,"given":"Nadia","family":"Ahmed","sequence":"additional","affiliation":[{"name":"UCL Hospitals NHS Trust, London, UK"},{"name":"Bloomsbury Clinic, CNWL NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"key":"bibr1-09564624231195088","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz999"},{"key":"bibr2-09564624231195088","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010106"},{"key":"bibr3-09564624231195088","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2015.0147"},{"key":"bibr4-09564624231195088","volume-title":"Sustiva 600 mg film-coated tablets - summary of product characteristics (SmPC) - (emc)","author":"Bristol Myers Squibb Pharmaceuticals limited","year":"2021"},{"key":"bibr5-09564624231195088","volume-title":"Descovy 200 mg\/25 mg film coated tablets - summary of product characteristics (SmPC) - (emc)","author":"Gilead Sciences Ltd","year":"2022"},{"key":"bibr6-09564624231195088","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003025"},{"key":"bibr7-09564624231195088","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2017.053"},{"key":"bibr8-09564624231195088","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000530"},{"key":"bibr9-09564624231195088","first-page":"1137","volume":"72","author":"Madelain V","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"bibr10-09564624231195088","volume-title":"BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update)","author":"Waters L","year":"2016"},{"key":"bibr11-09564624231195088","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31065-5"},{"key":"bibr12-09564624231195088","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30024-3"},{"key":"bibr13-09564624231195088","volume-title":"Email correspondence titled: Med info response to case 024385","author":"Gilead Sciences Ltd","year":"2022"},{"key":"bibr14-09564624231195088","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2003.22"},{"key":"bibr15-09564624231195088","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06311-11"},{"key":"bibr16-09564624231195088","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62187-X"},{"key":"bibr17-09564624231195088","doi-asserted-by":"publisher","DOI":"10.1124\/mol.108.045526"},{"key":"bibr18-09564624231195088","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182965d45"},{"key":"bibr19-09564624231195088","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001744"},{"key":"bibr20-09564624231195088","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz068"},{"key":"bibr21-09564624231195088","volume-title":"Liverpool HIV Interactions","author":"University of Liverpool","year":"2023"},{"key":"bibr22-09564624231195088","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000027047"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624231195088","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09564624231195088","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624231195088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:44:55Z","timestamp":1777675495000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09564624231195088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":22,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1177\/09564624231195088"],"URL":"https:\/\/doi.org\/10.1177\/09564624231195088","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,18]]}}}